204 related articles for article (PubMed ID: 29500147)
1. A Retrospective Study of Double-hit Lymphomas in Elderly Patients (Aged > 70 Years): Overall Outcomes.
Hancock C; Knouse P; Almanaseer I; Bitran J
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):280-285. PubMed ID: 29500147
[TBL] [Abstract][Full Text] [Related]
2. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
Kühnl A; Cunningham D; Counsell N; Hawkes EA; Qian W; Smith P; Chadwick N; Lawrie A; Mouncey P; Jack A; Pocock C; Ardeshna KM; Radford J; McMillan A; Davies J; Turner D; Kruger A; Johnson PW; Gambell J; Rosenwald A; Ott G; Horn H; Ziepert M; Pfreundschuh M; Linch D
Ann Oncol; 2017 Jul; 28(7):1540-1546. PubMed ID: 28398499
[TBL] [Abstract][Full Text] [Related]
3. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.
Howlett C; Snedecor SJ; Landsburg DJ; Svoboda J; Chong EA; Schuster SJ; Nasta SD; Feldman T; Rago A; Walsh KM; Weber S; Goy A; Mato A
Br J Haematol; 2015 Aug; 170(4):504-14. PubMed ID: 25907897
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
Godfrey JK; Nabhan C; Karrison T; Kline JP; Cohen KS; Bishop MR; Stadler WM; Karmali R; Venugopal P; Rapoport AP; Smith SM
Cancer; 2019 Jun; 125(11):1830-1836. PubMed ID: 30707764
[TBL] [Abstract][Full Text] [Related]
6. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
7. Inferior survival in high-grade B-cell lymphoma with
McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
[TBL] [Abstract][Full Text] [Related]
8. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
9. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of
Rosenwald A; Bens S; Advani R; Barrans S; Copie-Bergman C; Elsensohn MH; Natkunam Y; Calaminici M; Sander B; Baia M; Smith A; Painter D; Pham L; Zhao S; Ziepert M; Jordanova ES; Molina TJ; Kersten MJ; Kimby E; Klapper W; Raemaekers J; Schmitz N; Jardin F; Stevens WBC; Hoster E; Hagenbeek A; Gribben JG; Siebert R; Gascoyne RD; Scott DW; Gaulard P; Salles G; Burton C; de Jong D; Sehn LH; Maucort-Boulch D
J Clin Oncol; 2019 Dec; 37(35):3359-3368. PubMed ID: 31498031
[TBL] [Abstract][Full Text] [Related]
12. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.
Dunleavy K
Curr Treat Options Oncol; 2015 Dec; 16(12):58. PubMed ID: 26634708
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy.
Tumati V; Trivedi L; Li HC; Patel P; Scaglioni PP; Vusirikala M; Sadeghi N; Rizvi S; Chen W; Wachsmann J; Collins R; Desai NB
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1126-1132. PubMed ID: 29722657
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
Chen AI; Leonard JT; Okada CY; Gay ND; Chansky K; Fan G; Dunlap JB; Raess PW; Braziel RM; Stentz A; Maziarz RT
Leuk Lymphoma; 2018 Aug; 59(8):1884-1889. PubMed ID: 29199519
[TBL] [Abstract][Full Text] [Related]
15. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
Landsburg DJ; Falkiewicz MK; Maly J; Blum KA; Howlett C; Feldman T; Mato AR; Hill BT; Li S; Medeiros LJ; Torka P; Hernandez-Ilizaliturri F; Reddy NM; Singavi A; Fenske TS; Chavez JC; Kaplan JB; Behdad A; Petrich AM; Bast MA; Vose JM; Olszewski AJ; Costa C; Lansigan F; Gerson JN; Barta SK; Calzada O; Cohen JB; Lue JK; Amengual JE; Rivera X; Persky DO; Peace DJ; Nathan S; Cassaday RD
J Clin Oncol; 2017 Jul; 35(20):2260-2267. PubMed ID: 28475457
[TBL] [Abstract][Full Text] [Related]
17. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
18. Genetics and diffuse large B-Cell lymphoma.
Niroula R; Butera J
R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
[TBL] [Abstract][Full Text] [Related]
19. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
Herrera AF; Mei M; Low L; Kim HT; Griffin GK; Song JY; Merryman RW; Bedell V; Pak C; Sun H; Paris T; Stiller T; Brown JR; Budde LE; Chan WC; Chen R; Davids MS; Freedman AS; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; Murata-Collins J; Nademanee AP; Palmer JM; Pihan GA; Pillai R; Popplewell L; Siddiqi T; Sohani AR; Zain J; Rosen ST; Kwak LW; Weinstock DM; Forman SJ; Weisenburger DD; Kim Y; Rodig SJ; Krishnan A; Armand P
J Clin Oncol; 2017 Jan; 35(1):24-31. PubMed ID: 28034071
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on chemotherapy for the management of double-hit lymphoma.
Al-Juhaishi T; Mckay J; Sindel A; Yazbeck V
Expert Opin Pharmacother; 2020 Apr; 21(6):653-661. PubMed ID: 32066288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
